Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 845 2813

Website: www.sab.bio

Address:

777 W 41st St., Miami Beach, United States

rispi May. 13 at 12:08 PM

$SABS https://pmc.ncbi.nlm.nih.gov/articles/PMC12905621/pdf/main.pdf

1 · Reply

rispi May. 13 at 7:40 AM

$SABS H.C. Wainwright raised its price target on SAB Biotherapeutics stock (NASDAQ:SABS) to $10 from $7 while maintaining a Buy rating, citing lower diluted shares outstanding than previously estimated. The stock has delivered an 88% return over the past year, though shares currently trade at $3.58, down from their 52-week high of $6.60.

0 · Reply

rispi May. 13 at 7:00 AM

$SABS The company received written confirmation from the FDA that C-peptide may serve as a surrogate endpoint for accelerated approval, de-risking their regulatory path.

0 · Reply

rispi May. 12 at 6:23 PM

$SABS SAB Biotherapeutics says FDA confirms C‑peptide AUC surrogate endpoint supporting potential accelerated approval for SAB‑142 SAB Biotherapeutics reports Q1 2026 results, covering its most recent quarter's financial and operational performance. Company highlights $217.6 million in cash, providing runway through 2028.

1 · Reply

MarketBeat May. 12 at 5:16 PM

https://marketbeat.com/a/8650816/ $SABS SAB Biotherapeutics Q1 Earnings Call Highlights

0 · Reply

Cinderblocks May. 12 at 2:10 PM

$SABS This selling seems a bit ridiculous. Expenses are up because R&D investments. That's not necessarily a bad thing for a biotech. Plenty of cash.

1 · Reply

EarningsInsider May. 12 at 1:30 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-sab-biotherapeutics-stock/ $SABS SAB Biotherapeutics Earnings Transcript

0 · Reply

rispi May. 12 at 11:41 AM

$SABS https://finviz.com/news/353305/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights Cash Position: Cash, cash equivalents, and available for sale securities of $217.6 million at March 31, 2026, providing operational runway through 2028.

0 · Reply

rispi May. 12 at 7:07 AM

$SABS a few hours to earnings and conference

0 · Reply

cryptoguyinc May. 11 at 2:34 PM

$SABS needed a manufactured pullback so hedgies and Pelosi’s wealth manager could load up before the jump

1 · Reply

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

May 12, 2026, 8:30 AM EDT - 1 day ago

SAB Biotherapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 7:30 AM EDT - 1 day ago

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 5, 2026, 8:30 AM EDT - 8 days ago

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

2026-04-29T12:30:52.000Z - 14 days ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

EBS

Apr 22, 2026, 7:00 AM EDT - 21 days ago

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

2026-04-02T11:26:22.000Z - 5 weeks ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

Mar 19, 2026, 4:01 PM EDT - 7 weeks ago

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-18T10:12:35.000Z - 2 months ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

Mar 17, 2026, 10:46 PM EDT - 2 months ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-17T21:35:16.000Z - 2 months ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

2026-03-17T20:05:50.000Z - 2 months ago

SAB Biotherapeutics announces common stock offering, no amount given

Mar 17, 2026, 4:01 PM EDT - 2 months ago

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-03-10T23:25:30.000Z - 2 months ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

2026-03-10T11:41:43.000Z - 2 months ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

Mar 10, 2026, 7:31 AM EDT - 2 months ago

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Mar 9, 2026, 5:16 PM EDT - 2 months ago

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 3:00 PM EDT - 2 months ago

SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:00 AM EST - 2 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:40 AM EST - 2 months ago

SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:30 AM EST - 3 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 15, 2026, 10:30 AM EST - 4 months ago

SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T13:27:50.000Z - 4 months ago

SAB Biotherapeutics initiated with a Buy at UBS

2026-01-07T13:12:17.000Z - 4 months ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

Jan 7, 2026, 8:00 AM EST - 4 months ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 6, 2026, 8:00 AM EST - 4 months ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-30T15:15:19.000Z - 4 months ago

SAB Biotherapeutics files $300M mixed securities shelf

2025-12-19T11:36:31.000Z - 5 months ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

2025-12-18T13:05:56.000Z - 5 months ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

Dec 18, 2025, 8:00 AM EST - 5 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

2025-12-17T13:12:49.000Z - 5 months ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

Dec 17, 2025, 8:00 AM EST - 5 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

2025-12-08T13:26:26.000Z - 5 months ago

SAB Biotherapeutics to present data on progress in development of SAB-142

Dec 8, 2025, 8:00 AM EST - 5 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 2, 2025, 3:50 PM EST - 5 months ago

SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 13, 2025, 5:00 PM EST - 6 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 12, 2025, 10:00 AM EST - 6 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 2:45 PM EST - 6 months ago

SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 8:30 AM EST - 6 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

2025-09-19T11:30:17.000Z - 8 months ago

SAB Biotherapeutics highlights data in multiple presentations at EASD

Sep 19, 2025, 7:24 AM EDT - 8 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

2025-09-17T11:00:33.000Z - 8 months ago

SAB Biotherapeutics initiated with an Outperform at Leerink

Sep 3, 2025, 4:05 PM EDT - 8 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Aug 7, 2025, 7:30 AM EDT - 9 months ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Jul 21, 2025, 7:30 AM EDT - 10 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

May 9, 2025, 9:00 AM EDT - 1 year ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Mar 31, 2025, 7:32 AM EDT - 1 year ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Feb 12, 2025, 10:00 AM EST - 1 year ago

SAB Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

SAB Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 2 years ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 2 years ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

rispi May. 13 at 12:08 PM

$SABS https://pmc.ncbi.nlm.nih.gov/articles/PMC12905621/pdf/main.pdf

1 · Reply

rispi May. 13 at 7:40 AM

0 · Reply

rispi May. 13 at 7:00 AM

$SABS The company received written confirmation from the FDA that C-peptide may serve as a surrogate endpoint for accelerated approval, de-risking their regulatory path.

0 · Reply

rispi May. 12 at 6:23 PM

1 · Reply

MarketBeat May. 12 at 5:16 PM

https://marketbeat.com/a/8650816/ $SABS SAB Biotherapeutics Q1 Earnings Call Highlights

0 · Reply

Cinderblocks May. 12 at 2:10 PM

$SABS This selling seems a bit ridiculous. Expenses are up because R&D investments. That's not necessarily a bad thing for a biotech. Plenty of cash.

1 · Reply

EarningsInsider May. 12 at 1:30 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-sab-biotherapeutics-stock/ $SABS SAB Biotherapeutics Earnings Transcript

0 · Reply

rispi May. 12 at 11:41 AM

0 · Reply

rispi May. 12 at 7:07 AM

$SABS a few hours to earnings and conference

0 · Reply

cryptoguyinc May. 11 at 2:34 PM

$SABS needed a manufactured pullback so hedgies and Pelosi’s wealth manager could load up before the jump

1 · Reply

rispi May. 11 at 2:20 PM

$SABS

0 · Reply

zippewa May. 11 at 1:30 PM

$SABS guessing 2steps back today…still bull tho!

0 · Reply

TrumpXTrades May. 11 at 12:03 PM

$SABS When does this 🚀 Some researchers describe SAB-163 as one of the most advanced antibody-based hantavirus countermeasures currently known outside convalescent plasma approaches

2 · Reply

rispi May. 11 at 11:12 AM

$SABS one day to the conference call, though if they spell the word “hantavirus” , could be a quick 4X of SP. The only. As I wrote

0 · Reply

rispi May. 11 at 10:22 AM

$INO $MRNA $NVAX $SABS

0 · Reply

rispi May. 11 at 9:45 AM

$SABS it seems the Big BoyZ start cover our tiny honey!

0 · Reply

StocktwitsNews May. 11 at 8:22 AM

MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak $MRNA $NVAX $INO $SABS https://stocktwits.com/news/equity/markets/mrna-ino-sabs-nvax-stocks-jump-on-hantavirus-outbreak-fears/cZX9zT7ReWn

0 · Reply

rispi May. 11 at 7:47 AM

$SABS https://finviz.com/news/350711/sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et

0 · Reply

AlertsAndNews May. 10 at 9:57 PM

$INO $TRAW $SIGA $SABS $EBS French passenger of hantavirus cruise ship starts showing symptoms on evacuation flight, prime minister says-CBS "French citizen on a repatriation flight began showing symptoms of hantavirus after being evacuated from the cruise ship that was hit with the deadly outbreak, the country's prime minister said Sunday afternoon. Passengers began disembarking Sunday morning after the ship docked in Spain's Canary Islands."

1 · Reply

Quid_Pro_Quo May. 10 at 8:01 PM

$SABS The Hantavirus fear isn’t over yet

1 · Reply

AlertsAndNews May. 9 at 8:50 PM

$SABS $MRNA $INO $EBS $CODX WHO Classifies All 150 Aboard Hantavirus Ship as High-Risk, Orders 42-Day Monitoring The World Health Organization said Saturday that every person aboard the MV Hondius — nearly 150 passengers and crew — should be classified as a high-risk contact following a deadly hantavirus outbreak that has killed three people. WHO pandemic preparedness director Maria Van Kerkhove said active monitoring of all individuals upon disembarkation is recommended for a full 42-day period. No passengers or crew are currently showing symptoms, though the ship is heading toward waters off Tenerife, where UK officials are preparing to isolate cruise ship passengers in a former Covid hospital.

2 · Reply

rispi May. 9 at 5:12 PM

$SABS $PFE Fact Check: Hantavirus infection is not a confirmed side effect of Pfizer’s COVID-19 vaccine - https://www.reuters.com/fact-check/hantavirus-infection-is-not-confirmed-side-effect-pfizers-covid-19-vaccine-2026-05-08/

2 · Reply

Market Cap	189.54M
Revenue (ttm)	0.00
Net Income (ttm)	13.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	836,400
Avg Vol	863,674
Day's Range	N/A - N/A
Shares Out	50.95M
Stochastic %K	15%
Beta	0.55
Analysts	Strong Sell
Price Target	$9.89